Edgewise Therapeutics (EWTX) Preferred Stock Liabilities (2020)

Edgewise Therapeutics' (EWTX) quarterly Preferred Stock Liabilities came in at $160.2 million in Q4 2020.

Edgewise Therapeutics (EWTX) Preferred Stock Liabilities (2020) Analysis & Trends

Edgewise Therapeutics has disclosed Preferred Stock Liabilities across 1 years of filings, most recently posting $160.2 million for Q4 2020.

Preferred Stock Liabilities for Q4 2020 came in at $160.2 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $160.2 million (changed N/A YoY), and the FY2020 annual result was $160.2 million, changed N/A from the prior year.
Preferred Stock Liabilities came in at $160.2 million for Q4 2020 at Edgewise Therapeutics.
In the past five years, Preferred Stock Liabilities ranged from a high of $160.2 million in Q4 2020 to a low of $160.2 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Edgewise Therapeutics	3.52 Bn	3.52 Bn	-	-

Download Data

Date	Value
Dec 31, 2020	160.21 Mn